Difelikefalin相关不良事件信号:FAERS数据库真实世界药物警戒研究
本研究基于FAERS数据库(2022-2025)提取328例Difelikefalin相关不良事件报告,采用ROR和PRR进行失衡分析。结果显示神经系统疾病和精神病类疾病信号最强,高风险信号包括精神状态改变、定向障碍、电击感、嗜睡、跌倒和骨折。研究提示老年血液透析患者是Difelikefalin相关不良事件的高危人群,需针对性临床监测。
要点
- Difelikefalin相关不良事件以神经系统和精神病类疾病信号最强。
- 高风险信号包括精神状态改变、定向障碍、电击感、嗜睡、跌倒和骨折。
- 老年血液透析患者是Difelikefalin相关不良事件的高危人群。
核心结论
- Difelikefalin相关不良事件以神经精神类安全信号为主,老年患者风险尤其升高。
- 所有信号需前瞻性队列研究验证潜在因果关系。
研究设计与样本
- 基于FAERS数据库(2022-2025)的药物警戒研究,共纳入328例Difelikefalin相关不良事件报告。
- 采用Medex UIMA标准化药物名称,MedDRA编码不良事件,使用ROR和PRR进行失衡分析。
主要发现
- 最常见结局为其他严重事件(46.01%)、住院(33.46%)和死亡(15.59%)。
- 系统器官分类层面,神经系统疾病ROR=3.4,精神病类疾病ROR=2.99。
- 首选术语层面,精神状态改变ROR=85.65,定向障碍ROR=33.62,电击感ROR=32.09,嗜睡ROR=16.25,跌倒ROR=8.46,骨折ROR=21.06。
- 发现III期临床试验未报告的罕见信号(如电击感、定向障碍)具有显著失衡报告。
临床怎么用
- 对接受Difelikefalin治疗的血液透析患者,尤其是老年患者,应加强神经精神类不良事件的临床监测。
局限性
- Difelikefalin获批时间较近且真实世界使用有限,报告数量有限。
- 所有信号需前瞻性队列研究验证潜在因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Difelikefalin, a peripherally acting selective κ-opioid receptor agonist, is approved for treating chronic kidney disease-associated pruritus (CKD-aP) in adults on hemodialysis. However, real-world data on its adverse drug events (ADEs) remain limited. This study aimed to systematically identify ADE signals associated with difelikefalin in hemodialysis patients using the FAERS database, to generate hypotheses for subsequent clinical validation and provide targeted evidence for safe clinical application of difelikefalin in this vulnerable population. METHODS: ADE reports related to difelikefalin were extracted from the FAERS database (2022-2025). Drug names were standardized using Medex UIMA, and ADEs were coded according to the Medical Dictionary for Regulatory Activities (MedDRA). Disproportionality analyses, including the reporting odds ratio (ROR) and proportional reporting ratio (PRR), were employed to detect ADE signals. RESULTS: A total of 328 difelikefalin-related ADE reports were included, which is limited by the relatively recent approval and limited real-world use of this agent. Demographically, male patients (49.09%) outnumbered females (24.09%), and the vast majority of patients with clear age data were aged 65 years or older. Clinically, the most frequent outcomes were 'other serious' events (46.01%), hospitalization (33.46%), and death (15.59%). At the System Organ Class (SOC) level, Nervous system disorders (ROR = 3.4) and Psychiatric disorders (ROR = 2.99) showed the strongest ADE signals. At the Preferred Term (PT) level, high-risk signals included mental status changes (ROR = 85.65), disorientation (ROR = 33.62), electric shock sensation (ROR = 32.09), somnolence (ROR = 16.25), fall (ROR = 8.46), and fracture (ROR = 21.06). We also identified several rare ADE signals unreported in phase III clinical trials (e.g. electric shock sensation, disorientation) with significant disproportional reporting. CONCLUSION: This pharmacovigilance study identifies potential neuropsychiatric safety signals associated with difelikefalin, with a particularly elevated risk in elderly patients. These findings identify elderly hemodialysis patients as the high-risk group for difelikefalin-related ADEs, and suggest the need for targeted clinical monitoring strategies for this population; all signals require prospective cohort studies to validate potential causal relationships.
引用
- Zhao J, Qiu Q, Zhang J, et al. Difelikefalin-associated adverse drug event signals: a real-world pharmacovigilance study from the FAERS database. Nephrol Dial Transplant. 2026. PMID: 42329786. doi:10.1093/ndt/gfag144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。